Gross Medicaid Prescription Drug Spending

Medicaid's gross spending on prescription drugs reached approximately $103.6 billion in fiscal year 2024, highlighting the program's massive role in the U.S. pharmaceutical market. This total represents expenditures before the application of federal and state rebates, which are mandatory for manufacturers seeking coverage under the Medicaid Drug Rebate Program. These figures provide a critical baseline for the pharmaceutical sector to evaluate market scale and the financial implications of state-level drug utilization.

According to KFF analysis of CMS data, the United States reached a gross Medicaid prescription drug spending total of $103,580,049,116 in fiscal year 2024. California recorded the highest state-level expenditure at $14,833,143,792, followed by New York at $10,396,952,730. Other significant contributors to the national total included Ohio at $4,512,455,758, Pennsylvania at $4,496,213,277, and Virginia at $4,447,631,065. These figures are based on the State Drug Utilization Data (SDUD), which is updated quarterly and reflects outpatient drugs paid for by states.

The reported gross spending represents the cost of drugs before any rebates are applied under the Medicaid Drug Rebate Program (MDRP). Under this program, pharmaceutical manufacturers must rebate a portion of drug payments to the government to ensure their FDA-approved products are covered by Medicaid. In addition to these federal statutory rebates, most states negotiate supplemental rebates with manufacturers to further reduce net costs. Consequently, the gross figures reported by KFF do not reflect the actual net spending by states after these financial concessions are processed.

Data reporting is subject to specific limitations, including the suppression of records by CMS for privacy reasons. Specifically, cells with fewer than 11 prescriptions are excluded from both national and state data to comply with the HIPAA Privacy Rule and the Federal Privacy Act. Because fewer records are suppressed at the national level than at the state level, the sum of all state spending is less than the reported national total. Historical data from MACPAC indicates that such suppression accounted for approximately 0.9% of gross spending in previous cycles, though the exact impact for FY 2024 remains a factor in data misalignment.

For the pharmaceutical industry, these metrics underscore the high volume of Medicaid-covered prescriptions and the complexity of the rebate-driven pricing model. The requirement for Medicaid to cover almost all drugs from participating manufacturers ensures broad market access but necessitates significant financial give-backs from pharmaceutical companies. As state-level spending continues to reach billions of dollars in major markets like Texas ($3,542,175,651) and Florida ($3,317,346,541), the industry must navigate both federal mandates and state-specific supplemental negotiations that impact net revenue.